机构：[1]Institute for Breast Health Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China四川大学华西医院[2]Department of Pancreatic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China四川大学华西医院[3]College of Chemical Engineering, Shijiazhuang University, Shijiazhuang, Hebei, China.[4]Department of Biotherapy, West China Hospital and State Key Laboratory of Biotherapy, Sichuan University, Chengdu, Sichuan, China四川大学华西医院
This work was funded by the
National Natural Science Foundation of China (82172634, 22105137, 82273030,
82304527); the National Key R&D Program of China (2022YFA1207300
(2022YFA1207303), 2022YFC2504700 (2022YFC2504703)); the Key Program of
the Science and Technology Bureau of Sichuan, China (2021YFSY0007,
24NSFSC7798, 24NSFSC8155); 1.3.5 projects for disciplines of excellence, West
China Hospital, Sichuan University (ZYYC20013).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类|1 区生物学
小类|2 区细胞生物学
最新[2023]版：
大类|1 区生物学
小类|2 区细胞生物学
第一作者：
第一作者机构：[1]Institute for Breast Health Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Liu Xiaowei,Zuo Fengli,Song Jinen,et al.Immune checkpoints HLA-E:CD94-NKG2A and HLA-C:KIR2DL1 complementarily shield circulating tumor cells from NK-mediated immune surveillance[J].Cell Discovery.2024,10(1):16.doi:10.1038/s41421-024-00646-3.
APA：
Liu Xiaowei,Zuo Fengli,Song Jinen,Tang Leyi,Wang Xueyan...&Shi Hubing.(2024).Immune checkpoints HLA-E:CD94-NKG2A and HLA-C:KIR2DL1 complementarily shield circulating tumor cells from NK-mediated immune surveillance.Cell Discovery,10,(1)
MLA：
Liu Xiaowei,et al."Immune checkpoints HLA-E:CD94-NKG2A and HLA-C:KIR2DL1 complementarily shield circulating tumor cells from NK-mediated immune surveillance".Cell Discovery 10..1(2024):16
